Can We Do It Better: Managing Atrial Fibrillation in Patients with Structural Heart Disease

Cardiology
Curriculum:
Improving Outcomes in the Management of Patients with Atrial Fibrillation
Credits:
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
December 11, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

cardiologists; electrophysiologists; and primary care providers

Relevant Terms:

Atrial Fibrillation

Bruce S. Stambler, M.D. 

Bruce S. Stambler, M.D.
Director of Cardiac Arrhythmia Research and Education
Piedmont Heart Institute
Atlanta, GA

Bruce Stambler, M.D., earned his medical degree from Duke University School of Medicine.  He completed his internal medicine residency and clinical and research fellowship in cardiology at Beth Israel Hospital, Harvard Medical School in Boston, Massachusetts.  He then completed a clinical and research fellowship in cardiac electrophysiology at Massachusetts General Hospital in Boston, Massachusetts.

Prior to joining Piedmont Heart, Dr. Stambler practiced at University Hospitals of Cleveland, where he served as Director of Clinical Electrophysiology and Pacing and Director of the Electrophysiology Fellowship Program. He was a Professor of Medicine at Case Western Reserve University in Cleveland, Ohio.  He is board certified in cardiology and cardiac electrophysiology. He was consistently selected as a Best/Top Doctor in America from 2004-2014.  A fellow of the American College of Cardiology, American Heart Association and the Heart Rhythm Society, Dr. Stambler is very active in research and education in cardiac electrophysiology.  At Piedmont Heart, he serves as Director of Cardiac Arrhythmia Research and Education. 

Peter R. Kowey, MD, FACC

Peter R. Kowey, MD, FACC
Professor of Medicine and Clinical Pharmacology
Jefferson Medical College
Chief, Division of Cardiovascular Diseases
Main Line Health System
The William Wikoff Smith Chair in Cardiovascular Research
Lankenau Hospital and Medical Research Center
Wynnewood, Pennsylvania

Peter R. Kowey, MD, is a graduate of St Joseph’s University and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. He completed his residency training in internal medicine at Penn State University and was a Fellow in cardiovascular medicine and research at the Harvard University School of Public Health, the Peter Bent Brigham Hospital, and the West Roxbury VA Hospital. After this training he joined the faculty at the Medical College of Pennsylvania as Director of the CCU and Arrhythmia Program, and rose to the rank of full Professor. He went on to become Chief of the Division of Cardiovascular Diseases at the Lankenau Hospital Main Line Health System and President of the Main Line Health Heart Center and is the William Wikoff Smith Chair in Cardiovascular Research. He also is Professor of Medicine and Clinical Pharmacology at Jefferson Medical College.

Dr. Kowey is a Fellow of several professional organizations including the Clinical Council of the American Heart Association, the American College of Cardiology, the American College of Physicians, the College of Physicians of Philadelphia, the American College of Chest Physicians, and the American College of Clinical Pharmacology. He was a founding member of the Philadelphia Arrhythmia Group and a charter member of the North American Society of Pacing and Electrophysiology. He has served on numerous committees for each of these organizations including program and abstract review committees for national and international programs. He spent 9 years as a member of the Cardiorenal Drug Advisory Committee, 4 years on the Cardiovascular Devices Committee of the Food and Drug Administration, and was on the Expert Advisory Panel of the US Pharmacopeial convention.

Dr. Kowey’s principal area of interest has been cardiac rhythm disturbances. He has been the recipient of over 150 grants and has authored or co-authored over 400 papers and scientific reports. His group has participated in a large number of pivotal clinical trials, many directed by Dr. Kowey himself. He is the co-editor of 3 textbooks regarding cardiac arrhythmia. He is a referee for manuscript review for 25 journals and sits on the editorial boards of the Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology. He has provided consultation to over 60 international pharmaceutical companies and chaired several data and safety monitoring boards for clinical trials.

While working with industry, he has pioneered the development of many antiarrhythmic drugs and antitachycardia devices that are used around the world for the treatment of patients with life-threatening cardiac rhythm problems. Dr. Kowey also maintains a busy consultative arrhythmia practice and has been recognized as a leader in his field in several international publications.

Ty J. Gluckman, MD, FACC, FAHA

Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Clinical Excellence
Providence Heart and Vascular Institute, Oregon Region
Portland, Oregon

Dr. Ty J. Gluckman is Director of Clinical Excellence at the Heart and Vascular Institute of Providence St. Vincent Medical Center in Portland, Oregon and an adjunct member of the The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland. Dr. Gluckman graduated summa cum laude with highest honors from Brandeis University. He received his medical degree from Northwestern University Medical School and did his internal medicine training at McGaw Medical Center of Northwestern University, where he remained for additional years as chief resident and an Instructor in Medicine. He completed his cardiology fellowship training at the Johns Hopkins Hospital and served as chief fellow during his final year there. His principal clinical and research interests include the management of acute coronary syndromes, the evaluation of premature graft failure after coronary artery bypass graft surgery, and variability in responsiveness to antiplatelet agents. Dr. Gluckman serves as co-editor of the National Preventive Cardiology CME Newsletter Cardiology News and Issues in the New Millennium, which has a circulation of nearly 100,000 physicians and has recent publications in the Archives of Internal Medicine, JAMA, and the Journal of the American College of Cardiology. He is an active councilor and Director of Quality for the State of Oregon Chapter of the American College of Cardiology, a board member of the Portland Metro and SW Washington Chapter of the American Heart Association, and associate editor for clinical documents and practice guidelines for Cardiosource.

1. Assess the clinical, economic, and quality-of-life impact of atrial fibrillation (AF).
2. Outline the benefits and risks of rate, rhythm, and ablation strategies for the management of AF.
3. Review the safety, efficacy, and strategies for selection of antiarrhythmic therapy for AF.
4. Select appropriate AF patients for rate, rhythm, or ablation therapy in accordance with current guideline recommendations to optimize outcomes.

LAUNCH DATE/EXPIRATION DATE
This activity was launched on December 6, 2018 and will expire on December 6, 2019.
 
TARGET AUDIENCE
This activity has been designed to meet the educational needs of cardiologists, electrophysiologists, primary care providers (MDs/DOs), nurse practitioners (NPs) and physician assistants (PAs) who practice in a primary care setting and other health care professionals involved in the care of patients with atrial fibrillation.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
HOW TO CLAIM CREDIT
Statement of credit will be available to print from your user history page.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
 
Name of Faculty Reported Financial Relationship
Bruce Stambler, MD
Dr. Stambler discloses no relevant financial relationships with an ACCME-defined commercial interest during the past 12 months.
Peter Kowey, MD Dr. Kowey has served as a consultant for Boehringer Ingelheim, Johnson & Johnson, Sanofi and Pfizer.
 
 
OTHER CONTRIBUTOR/PLANNER DISCLOSURES
Ty Gluckman, MD, FACC, FAHA provided external review for this activity.  Dr. Gluckman discloses no relevant financial relationships with an ACCME-defined commercial interest during the past 12 months.
 
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
 
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
 
SUPPORTER ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Sanofi US.


COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above